Table 2 Correlation analysis between FXYD2 mRNA expression and overall survival among 516 glioma patients in CGGA
Parameter | Univariate Cox Regression | Multivariate Cox Regression | ||||
|---|---|---|---|---|---|---|
P value | HR | 95% CI (low-up) | P value | HR | 95% CI (low-up) | |
Sex | 0.447 | 1.091 | 0.871–1.366 |  |  |  |
Age | 0.000 | 1.027 | 1.017–1.036 | 0.002 | 1.015 | 1.005–1.024 |
Recurrent | 0.000 | 2.117 | 1.690–2.651 | 0.000 | 2.118 | 1.672–2.684 |
Histopathological types (HE) | 0.000 | 1.827 | 1.657–2.015 | 0.333 | 0.896 | 0.719–1.118 |
2021 WHO glade | 0.000 | 2.804 | 2.377–3.308 | 0.000 | 2.717 | 1.914–3.856 |
IDH mutation status | 0.000 | 0.321 | 0.256–0.403 | 0.025 | 0.712 | 0.529–0.958 |
1p/19q codeletion status | 0.000 | 0.282 | 0.199–0.400 | 0.000 | 0.403 | 0.265–0.611 |
MGMT methylation_status | 0.004 | 0.790 | 0.674–0.926 | 0.041 | 0.841 | 0.713–0.993 |
Complete excision | 0.713 | 1.050 | 0.809-1.364 | 0.201 | 0.838 | 0.639–1.099 |
Radiotherapy | 0.467 | 1.109 | 0.839–1.465 | 0.244 | 0.825 | 0.598–1.140 |
Chemotherapy | 0.230 | 1.176 | 0.903–1.533 | 0.003 | 0.611 | 0.443–0.841 |
FXYD2 mRNA expression | 0.000 | 0.469 | 0.374–0.589 | 0.018 | 0.959 | 0.927–0.993 |